Platelet sensitivity to a prostacyclin analogue in systemic sclerosis

Area of Science:

• Cardiovascular Biology
• Rheumatology
• Vascular Medicine

Background:

• Vascular prostacyclin (PGI2) is crucial for regulating platelet function and blood flow.
• Systemic sclerosis (SS) is characterized by increased platelet aggregation (PA), but the platelet-PGI2 relationship is unclear.

Purpose of the Study:

• To investigate platelet sensitivity to a PGI2 analogue in patients with systemic sclerosis (SS).
• To explore the potential role of PGI2 insensitivity in the vascular pathology of SS.

Main Methods:

• Evaluated platelet sensitivity to the PGI2 analogue ZK36374 in 17 SS patients and 18 healthy controls.
• Measured the percentage inhibition of platelet aggregation (PA) at two different doses of ZK36374.
• Assessed changes in sensitivity in SS patients treated with prostaglandin E or nifedipine.

Main Results:

• SS platelets exhibited significantly reduced inhibition of PA by ZK36374 compared to controls at both tested doses.
• At 2 ng ZK36374, SS patients showed 19% inhibition vs. 60% in controls; at 3 ng, SS patients showed 47% inhibition vs. 82% in controls.
• Treatment with prostaglandin E or nifedipine in 11 SS patients normalized platelet sensitivity to PGI2.

Conclusions:

• Platelets in systemic sclerosis demonstrate reduced sensitivity to the inhibitory effects of prostacyclin (PGI2).
• This impaired PGI2 responsiveness may be a contributing factor to the vascular lesions observed in SS.
• The findings support a broader picture of cellular resistance to PGI2 effects.